Back

Off target effects of SGLT2-inhibitors

21 January 2025 (15:00 - 15:22)
Organised by: Logo
Seminar Presentation Part of: The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart Drugs, Drug Targets Delegate Premium access HFA Winter Research Meeting on Translational Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Assistant Professor Coert J Zuurbier

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
SGLT2-inhibitors and iron status in heart failure
Doctor J. Nunez Villota (Valencia, ES)
Slides
Presentation thumbnail
Metabolic alterations and post-translational modifications in the failing heart
Professor L. Bertrand (Brussels, BE)
Slides
Presentation thumbnail
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Professor R. De Boer (Rotterdam, NL)
Slides

Access the full session

Session thumbnail
The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart

The Event

Event poster

HFA Winter Research Meeting on Translational Heart Failure 2025

21 January 2025 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Safety of SGLT2-Inhibitors in cardio-oncology patients with heart failure undergoing cancer treatment
21 June 2025
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024
thumbnail
Congress Presentation
Effects of urinary tract infection and stopping sodium-glucose cotranspoter-2 inhibitors in patients with type 2 diabetes mellitus: a population-based study
26 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources